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Two decades have passed since the discovery of microRNA (miRNA), which determines
cell fate in nematodes. About one decade ago, the conservation of miRNA in humans was
also discovered. At present, the loss of certain miRNAs and the overexpression of miRNAs
have been demonstrated in many types of diseases, especially cancer. A key miRNA in
lung cancer was reported soon after the initial discovery of a tumor-suppressive miRNA
in a hematological malignancy. Various causes of miRNA disruption are known, including
deletions, mutations, and epigenetic suppression as well as coding genes. The recent
accumulation of knowledge regarding epigenetic transcriptional suppression has revealed
the suppression of several miRNAs in lung cancer in response to epigenetic changes, such
as H3K9 methylation prior to DNA methylation and H3K27 methylation independent of
DNA methylation. In this review, recent knowledge of miRNA disruption in lung cancer as
a result of epigenetic changes is discussed. Additionally, emerging cancer-speciﬁc changes
in RNA editing and their impact on miRNA function are described.
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MICRORNAs AND CANCER: A HISTORICAL PERSPECTIVE
MicroRNAs (miRNAs) are small non-coding RNA molecules
(approximately 22 nucleotides) that function as versatile regula-
tors of gene expression. miRNAs negatively regulate the expression
of thousands of genes through the destabilization and/or trans-
lational suppression of mRNAs by binding to complementary
sequences in the 3′ untranslated regions (3′UTRs) of target
mRNAs (Lee et al., 1993; Wightman et al., 1993).
The ﬁrst miRNA to be discovered, lin-4, was determined to be
an essential regulator of development in the nematodeCaenorhab-
ditis elegans (Lee et al., 1993; Wightman et al., 1993). This short
non-coding RNA was considered to be a peculiar constituent
speciﬁc to worms. Seven years passed before a second miRNA,
let-7, was discovered in nematodes (Reinhart et al., 2000). Shortly
thereafter, let-7 was found to be broadly conserved across many
species, includinghumans (Pasquinelli et al., 2000). In 2001, a large
number of such genes were identiﬁed, and the term “microRNA”
was coined (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and
Ambros, 2001). Currently, more than 2,000 mature miRNAs have
been documented in the miRNA registry (Sanger miRBase release
20; http://www.mirbase.org).
MicroRNAs are involved in many biological processes such as
cell cycle control, cell differentiation, and apoptosis. Alterations
in miRNA expression have been increasingly recognized as play-
ing important roles in the pathogenesis of human cancers. For
example, the ﬁrst tumor-suppressive miRNAs mir-15 and mir-
16 located at 13q14 are frequently deleted and downregulated in
chronic lymphocytic leukemia (Calin et al., 2002). In lung can-
cer, a reduction in let-7 expression is signiﬁcantly associated with
a shorter postoperative survival (Takamizawa et al., 2004). The
let-7 miRNAs target important oncogenes such as the Ras family
(Johnson et al., 2005) and HMGA2 (Mayr et al., 2007). The mir-
17-92 miRNA cluster, which was the ﬁrst oncogenic miRNA to
be reported, is ampliﬁed and over expressed in B cell lymphoma
(He et al., 2005). Moreover, the mir-17-92 miRNA cluster is also
ampliﬁed and overexpressed in small-cell lung cancer (SCLC) and
enhances the proliferation of cancer cells (Hayashita et al., 2005).
MicroRNAs can be used as biomarkers for the diagnosis and
prognosis of malignancies. In general,miRNA expression is down-
regulated in tumors, compared with normal tissues, and analyzes
of the expression of 217 miRNAs in various human cancers reﬂect
the developmental lineage and differentiation of the tumor (Lu
et al., 2005). Furthermore, certain miRNAs can aid in classifying
the histological subtype (adenocarcinoma or squamous cell carci-
noma) of lung cancer (Bishop et al., 2010). The miRNA signature
can also predict the survival and relapse of patients with lung
cancer (Yu et al., 2008).
Despite growing evidence of the involvement of miRNAs in
human carcinogenesis, limited information is available regard-
ing how miRNA expressions are deregulated in cancer. In this
article, we review the mechanisms responsible for the changes
in miRNA expression in lung cancer, focusing particularly on
epigenetic mechanisms, such as DNA methylation and histone
modiﬁcations.
MECHANISMS OF DEREGULATED miRNA EXPRESSION IN
CANCER
In animals, miRNAs are generally transcribed by RNA polymerase
II (Lee et al., 2004) to form primary transcripts (pri-miRNAs).
Pri-miRNAs form hairpin structures in the nucleus and are pro-
cessed by the Drosha/DGCR8 complex to form approximately
60 nt precursor miRNAs (pre-miRNAs; Gregory et al., 2004).
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Pre-miRNAs are transported to the cytoplasm through the RAN
GTP-dependent transporter exportin-5 (Lund et al., 2004) and are
cleaved by Dicer into mature miRNAs (Hutvagner et al., 2001;
Figure 1).
miRNA are frequently located at fragile sites as well as minimal
regions of loss of heterozygosity,minimal regions of ampliﬁcation,
or common breakpoint regions in cancer (Calin et al., 2004). In
addition to such genomic changes, any alteration in the miRNA
biogenesis pathway described above can affect miRNA expres-
sion in cancer. The currently known mechanisms responsible for
changes in miRNA expression in cancer include genomic dele-
tions or ampliﬁcations, chromosomal translocations, epigenetic
silencing by DNA methylation, and impairments of the miRNA
biogenesis pathway, such as the frameshift mutation of exportin-
5 (Melo et al., 2010), the downregulation of Dicer (Karube et al.,
2005;Merritt et al., 2008), and the frameshift mutation of TARBP2
(Melo et al., 2009).
As mentioned above, mir-15 and mir-16, located at 13q14,
are deleted in more than half of all cases of chronic lymphocytic
leukemia (Calin et al., 2002), and ampliﬁcation of the mir-17-92
miRNA cluster located at 13q31 is observed in B cell lymphoma
and SCLC (Hayashita et al., 2005; He et al., 2005). In addition,
mir-125b-1 is a target of the chromosomal translocation t(11,14)
in B-cell precursor acute lymphoblastic leukemia, and this translo-
cation results in mir-125b overexpression that is controlled by an
immunoglobulin heavy-chain gene regulatory element (Bousquet
et al., 2008; Chapiro et al., 2010). However, with regard to lung
cancer, no chromosomal translocations involving miRNAs have
been previously reported.
Kumar et al. (2007) reported that the impairment of themiRNA
biogenesis pathway in cancer results in the global downregula-
tion of miRNA and the enhancement of cellular transformation
and tumorigenesis. They demonstrated that the knockdown of
DGCR8, Drosha, or Dicer in cancer cells resulted in a pro-
nounced transformedphenotype and that the conditional deletion
of Dicer enhanced tumor development in a K-ras-induced mouse
model of lung cancer. Importantly, a reduction in Dicer expres-
sion is associated with a poor prognosis in patients with lung
cancer (Karube et al., 2005) and ovarian cancer (Merritt et al.,
2008). Interestingly, a germline mutation of Dicer1 has been
FIGURE 1 | miRNA biogenesis pathway. miRISC, microRNA-induced
silencing complex.
discovered in pleuropulmonary blastoma, a rare pediatric lung
tumor (Hill et al., 2009). These ﬁndings clearly demonstrate that
the miRNA biogenesis pathway plays a crucial role in normal lung
development and lung carcinogenesis. Frameshift mutations of
exportin-5 and TARBP2 have been reported in colorectal cancer
with microsatellite instability, but not in lung cancer (Melo et al.,
2009, 2010).
Epigenetic changes in cancer genomes, such as DNA
methylation and histone modiﬁcations, cause the silencing of
tumor suppressor genes and contribute to human carcinogene-
sis (Jones and Takai, 2001; Jones and Baylin, 2002; Herman and
Baylin, 2003). Recently, DNA methylation in cancerous tissue has
been shown to silencemiRNAs in cancer (Saito et al., 2006; Lujam-
bio et al., 2007). Saito et al. reported that the expression ofmir-127,
which is embedded in a CpG island, was induced by treatment
with the chromatin-modifying drugs 5-aza-2’-deoxycytidine and
4-phenylbutyric acid in a bladder cancer cell line. Lujambio et al.
analyzed the miRNA expression proﬁle of a colon cancer cell line,
which was genetically deﬁcient for the DNA methyltransferase
(DNMT) enzymes DNMT1 and DNMT3b, and identiﬁed the epi-
genetic silencing of mir-124a in various types of cancer, including
colon, breast, and lung cancers as well as leukemia and lymphoma.
As the epigenetic silencing of key tumor suppressor genes, such as
APC and p16INK4A, is a common event in lung carcinogenesis
(Takai et al., 2001; Sano et al., 2007; Brock et al., 2008; Kusak-
abe et al., 2010) and miRNA expression is altered in lung cancer
(Yanaihara et al., 2006), some miRNAs are thought to be silenced
by DNA methylation or histone modiﬁcation in lung cancer.
In fact, growing evidence demonstrates that epigenetic changes
contribute to miRNA silencing in lung cancer (Liu et al., 2013).
DNA METHYLATION AND miRNA EXPRESSION
The earliest papers on miRNA expression proﬁling in lung cancer
were published in 2006 (Volinia et al., 2006; Yanaihara et al., 2006).
These studies used miRNA microarrays and found that a high
level of mir-155 expression and a low level of let-7a-2 expression
were signiﬁcantly correlated with a poor survival of lung cancer
patients. The number of miRNA proﬁling studies in lung can-
cer has grown rapidly in recent years, and these studies have led
to the discovery of the role of miRNAs in lung carcinogenesis
and their potential as diagnostic, prognostic, or predictive mark-
ers (Rothschild, 2013). Vosa et al. performed a meta-analysis of
20 published miRNA expression proﬁling studies in lung cancer
and identiﬁed a meta-signature of seven up-regulated (mir-21,
mir-210, mir-182, mir-31, mir-200b, mir-205, and mir-183) and
eight down-regulated (mir-126-3p, mir-30a, mir-30d, mir-486-5p,
mir-451a, mir-126-5p, mir-143, and mir-145) miRNAs (Vosa et al.,
2013). Guan et al. (2012) also reported a meta-analysis of 14 pub-
lished miRNA expression proﬁling studies and their results agreed
well with those published by Vosa et al.
One approach to identifying epigenetically silenced miRNAs
is to analyze the miRNA expression proﬁle of cancer cells before
and after treatment with chromatin-modifying drugs. Lujambio
et al. analyzed the miRNA expression proﬁle of three metastatic
cancer cell lines with and without the DNMT inhibitor 5-aza-
2’-deoxycytidine and reported that the DNA methylation of
three miRNAs (mir-9, mir-34b/c, and mir-148a) was associated
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with the metastasis of human cancers including lung cancer
(Lujambio et al., 2008). Heller et al. analyzed the miRNA expres-
sion proﬁle changes in A549 lung cancer cells treated with
5-aza-2’-deoxycytidine and the histone deacetylase inhibitor tri-
costatin A and identiﬁed mir-9-3 and mir-193a as targets for
DNA methylation in non-small cell lung cancer (NSCLC; Heller
et al., 2012). Our research team analyzed the expressions of 55 in
silico selected candidate miRNAs treated with or without 5-aza-2’-
deoxycytidine and found that mir-34b/c and mir-126 are silenced
by DNA methylation in NSCLC (Watanabe et al., 2012). We also
revealed that the DNA methylation of mir-9-3, -124-2, and -124-3
was individually associated with an advanced T factor, and that the
methylation of multiple miRNA loci was associated with a poor
prognosis (Kitano et al., 2011). The correlation between miRNA
methylation and the T factor suggested that the DNAmethylation
of these miRNA loci accumulates during tumor progression. A list
of miRNAs that are silenced by DNA methylation in lung cancer
is shown in Table 1.
The mir-34 family is comprised of three miRNAs (mir-34a,
mir-34b, and mir-34c) that are derived from two transcripts (mir-
34a on chromosome 1 and mir-34b/c on chromosome 11). In
mice, mir-34a is ubiquitously expressed, with the highest expres-
sion being in the brain, whereas mir-34b/c is mainly expressed
in the lung (Bommer et al., 2007). The mir-34 genes induce cell
cycle arrest, cellular senescence, and apoptosis when ectopically
expressed (Bommer et al., 2007; He et al., 2007;Welch et al., 2007)
through the downregulation of multiple target genes such as Bcl-2,
CyclinD1,Cyclin E2,CDK4,CDK6, c-Myc, and c-Met (Hermeking,
2010). Moreover, mir-34s have been identiﬁed as direct targets of
the p53 transcription factor (Bommer et al., 2007; Corney et al.,
2007; He et al., 2007), and their expression is induced in response
to DNA damage or oncogenic stress. These results indicate that
mir-34s play a critical role in the tumor-suppressive program gov-
erned by p53. Interestingly, the chromosomal locus 1p36, where
mir-34a is located, has been proposed to harbor a tumor sup-
pressor gene, since a homozygous deletion at this locus has been
reported in neuroblastoma, and mir-34a has been identiﬁed as a
candidate tumor suppressor at this locus (Cole et al., 2008).
In lung cancer, mir-34a and mir-34b/c are targets of epige-
netic silencing byDNAmethylation (Lodygin et al., 2008; Gallardo
et al., 2009; Wang et al., 2011; Watanabe et al., 2012). In primary
NSCLC, a low mir-34a expression level is signiﬁcantly associated
with a high probability of relapse after surgery (Gallardo et al.,
2009). We previously reported that mir-34b/c is methylated in
41% of primary NSCLC cases and that mir-34b/c methylation is
associated with lymphatic invasion (Watanabe et al., 2012). The
DNA methylation of mir-34b/c is associated with a poorer prog-
nosis in patients with NSCLC (Wang et al., 2011). In addition, the
mir-34s are silenced by DNA methylation in SCLC (Tanaka et al.,
2012). In primary SCLC, mir-34a and mir-34b/c were methylated
in 15% and 67% of the cases, respectively. The CpG island methy-
lation of mir-34b/c has also been reported in colorectal cancer
(Toyota et al., 2008), oral squamous cell cancer (Kozaki et al.,
2008), melanoma, and breast cancer (Lujambio et al., 2008). Thus,
the epigenetic inactivation of mi-34s is a common event in human
cancer.
mir-34a and mir-34b/c are intergenic miRNAs, and their
expressions are regulated by the DNA methylation of their own
promoters. Importantly, many miRNA encoding sequences are
located within the introns of protein coding genes, and intronic
miRNAs are usually expressed in a coordinate manner along
with their host gene mRNAs (Baskerville and Bartel, 2005). We
previously reported that mir-126, which is located within the
intron of EGFL7, is silenced by the DNA methylation of its host
gene in NSCLC (Watanabe et al., 2012). mir-126 functions as a
tumor-suppressive miRNA, suppressing metastasis in breast can-
cer (Tavazoie et al., 2008) and inhibiting the invasionof NSCLCcell
lines by targeting Crk (Crawford et al., 2008). Moreover, mir-126
was recently reported to be an essential regulator of angiogenesis.
Vascular endothelial growth factor (VEGF)-A is a target of mir-
126, and the downregulation of mir-126 increases the activity of
VEGF-A in lung cancer (Liu et al., 2009). A reduction in mir-126
expression is signiﬁcantly associated with increased microvessel
density in oral squamous cell cancer (Sasahira et al., 2012) and
NSCLC (Jusufovic et al., 2012), suggesting a negative regulatory
role of mir-126 in tumor angiogenesis. In addition, decreased
mir-126 expression is signiﬁcantly associated with a shorter sur-
vival period in patients with NSCLC (Jusufovic et al., 2012). In
contrast, Donnem et al. demonstrated that an elevated level of
mir-126 expression is associated with a shorter survival period in
patients with NSCLC and that an elevated level of mir-126 expres-
sion was associated with an increase in VEGF-A expression in
Table 1 | miRNAs silenced by DNA methylation in lung cancer.
miRNA Target genes Reference
mir-9-3 Lujambio et al. (2008), Kitano et al. (2011), and Heller et al. (2012)
mir-34a, -34b/c Bcl-2, Cyclin D1, Cyclin E2, CDK4, CDK6, c-Myc, c-Met Lodygin et al. (2008), Lujambio et al. (2008), Gallardo et al. (2009),
Wang et al. (2011), Tanaka et al. (2012), andWatanabe et al. (2012)
mir-124-1, -124-2, -124-3 CDK6 Lujambio et al. (2007) and Kitano et al. (2011)
mir-126 Crk, VEGF-A Watanabe et al. (2012)
mir-148a TGIF2 Lujambio et al. (2008) and Chen et al. (2013)
mir-193a Heller et al. (2012)
mir-200, -205 ZEB1, ZEB2 Tellez et al. (2011)
mir-487b SUZ12, BMI1,WNT5A, MYC, K-ras Xi et al. (2013)
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NSCLC (Donnem et al., 2011). The targeted deletion of mir-126 in
mice impaired normal angiogenesis, suggesting a positive regula-
tory role ofmir-126 in angiogenesis (Wang et al., 2008). Additional
research is required to elucidate the relation between mir-126,
tumor angiogenesis, and tumor progression. Furthermore, we
reported that the DNA methylation of EGFL7 (a host gene of
mir-126) was only observed in 7% of the clinical samples that
were evaluated (Watanabe et al., 2012), which cannot completely
explain the frequent downregulation of this miRNA in NSCLC. In
fact, our analyzes of DNA methylation of the coding genes (Sano
et al., 2007; Kusakabe et al., 2010) andmiRNAs (Kitano et al., 2011;
Watanabe et al., 2012) revealed that the ratio of DNA methylation
is often quite low in primary NSCLCs. This low ratio of DNA
methylation may be a result of insufﬁcient DNA methylation fol-
lowing changes in histone modiﬁcation, rather than the result of
the coexistence of non-cancerous tissues, and may be responsible
for the low frequency of DNA methylation of mir-126 in primary
NSCLCs if the method used to detect DNA methylation is not
sufﬁciently sensitive.
Cigarette smoking is the most important risk factor for lung
cancer. Accumulating evidence suggests that tobacco induces the
epigenetic silencing of certain miRNAs in lung carcinogenesis
(Tellez et al., 2011; Xi et al., 2013). Tellez et al. reported that the
exposure of human bronchial epithelial cells (HBECs) to tobacco
carcinogens decreased the expressions of mir-200b, -200c, and -
205 and induced the epithelial-to-mesenchymal transition (EMT).
The mir-200 family and mir-205 function as key negative regula-
tors of the EMT through the direct targeting of ZEB1 and ZEB2
(Gregory et al., 2008; Park et al., 2008). InHBECs, tobacco carcino-
gens initially induced an increase in H3K27me3 (inactive closed
chromatin) and subsequently induced the DNA methylation of
sequences encoding these miRNAs. The loss of mir-200c expres-
sion as a result of DNA methylation has been shown to induce
an aggressive, invasive, and chemoresistant phenotype of NSCLC
(Ceppi et al., 2010). In addition, Shien et al. (2013) demonstrated
that a lung cancer cell line with acquired resistance to an EGFR
tyrosine kinase inhibitor exhibited EMT features and the down-
regulation of mir-200c as a result of DNA methylation. Xi et al.
reported that tobacco carcinogens induced the epigenetic silenc-
ing ofmir-487b and thatmir-487b functions as a tumor suppressive
miRNA in NSCLC by targeting SUZ12, BMI1,WNT5A,MYC, and
K-ras. These studies highlight the potential of epigenetic drugs to
reverse tobacco-induced reprogramming in lung cancer cells.
H3K27me3 AND miRNAs
Epigenetic silencing in mammalian cells is mediated by at
least two distinct histone modiﬁcations: histone H3 trimethy-
lation at lysine 27 (H3K27me3) and histone H3 dimethylation
and trimethylation at lysine 9 (H3K9me2 and H3K9me3). A
recent genome-wide study of histone modiﬁcations in prostate
cancer cells revealed H3K27me3 as a mechanism of tumor-
suppressor gene silencing in cancer that occurs independently
of promoter DNA methylation (Kondo et al., 2008). A poly-
comb group protein, EZH2, exhibits histone methyltransferase
activity with substrate speciﬁcity for H3K27 (Cao and Zhang,
2004). EZH2 overexpression is associated with a poor prog-
nosis in lung cancer, and the knockdown of EZH2 expression
decreases the growth and invasion of lung cancer cells (Huqun
et al., 2012). These ﬁndings suggest that aberrant H3K27me3 con-
tributes to tumor-suppressor gene silencing in lung cancer, but
genome-wide analyzes of H3K27me3 in lung cancer have not been
reported.
Recently, Au et al. (2012) analyzed the changes in miRNA
expression proﬁles induced by EZH2 knockdown and found that
some tumor-suppressive miRNAs (mir-139, -125b, -101, -200b,
and let-7c) are silenced by H3K27me3 in hepatocellular carci-
noma. In lung cancer,mir-212 is silenced by histonemodiﬁcations
rather than DNA methylation (Incoronato et al., 2011). Incoro-
nato et al. showed that increases in H3K27me3 and H3K9me2 are
observed in the mir-212 promoter region in the lung cancer cell
line Calu-1, which has a low mir-212 expression level. EZH2 may
exert its oncogenic function, at least in part, by silencing tumor-
suppressivemiRNAs, and further investigation is required to verify
the association between H3K27me3 and miRNA expression in
lung cancer.
miRNAs THAT TARGET EPIGENETIC MACHINERY
While miRNA expression is regulated by DNA methylation and
histone modiﬁcations, genes encoding the epigenetic machinery
are also targeted by miRNAs. The mir-29 family is the prototype
of such miRNAs (Fabbri et al., 2007). The mir-29 family is com-
prised of three miRNAs (mir-29a, mir-29b, and mir-29c) that are
derived from two transcripts (mir-29b-1/29a on chromosome 7
andmir-29b-2/29c on chromosome 1). Themir-29 family is highly
expressed in normal tissues and is downregulated inmany types of
human cancers including lung cancer (Yanaihara et al., 2006; Xu
et al., 2009). mir-29a reportedly functions as an anti-metastatic
and anti-proliferative miRNA in lung cancer (Muniyappa et al.,
2009). mir-29b has also been reported to function as an anti-
metastatic miRNA in lung cancer through the regulation of the
Src-ID1 pathway (Rothschild et al., 2012).
Recently, the mir-29 family was shown to directly target
DNMT3A and DNMT3B, two enzymes involved in de novo DNA
methylation (Fabbri et al., 2007). The expression of mir-29s is
inversely correlated with that of DNMT3A and DNMT3B in lung
cancer tissue, and the enforced expressionofmir-29s in lung cancer
cell lines restores the normal pattern of DNAmethylation, induces
the re-expression of methylation-silenced tumor suppressor genes
(such as FHIT and WWOX), and inhibits tumorigenicity both in
vitro and in vivo. mir-29b also induces PTEN expression through
the downregulation of DNAmethyltransferases (DNMTs) and the
subsequent hypomethylation of thePTEN promoter in a lung can-
cer xenograft model (Li et al., 2012). Samakoglu et al. (2012) also
report that a combination therapy consisting of an EGFR antibody
with cisplatin and gemcitabine induces mir-29b expression, the
downregulation of DNMT3b, and the hypomethylation of tumor-
suppressor genes in a lung cancer xenograft model. mir-29b has
also been shown to down-regulate DNMT1, an enzyme involved
in the maintenance of DNA methylation, indirectly by targeting
Sp1, a transactivator of the DNMT1 gene in leukemia (Garzon
et al., 2009).
In addition to DNMTs, miRNAs can also target histone mod-
iﬁcation enzymes. mir-449a/b is downregulated and directly
targets HDAC1, a histone deacetylase in lung cancer (Jeon et al.,
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2012). mir-101 reportedly targets EZH2, and the genomic loss
of mir-101 leads to the overexpression of EZH2 in prostate can-
cer cells (Varambally et al., 2008). These results clearly show a
strong interplay between miRNA and the epigenetic machin-
ery, providing new insights into the molecular mechanism
of aberrant DNA methylation and histone modiﬁcations in
cancer.
RNA EDITING OF miRNAs
The most prevalent type of RNA editing in humans is the
deamination of adenosine to inosine in double-stranded RNA
(A-to-I editing). This process is catalyzed by two family mem-
bers of adenosine deaminases acting on RNA (ADAR): ADAR1
and ADAR2. All known A-to-I edited sites have been attributed
to ADAR1 or ADAR2 (Zinshteyn and Nishikura, 2009). Inosine is
present in mRNA at tissue-speciﬁc levels that are correlated with
ADAR expression. Analyzes of the amount of inosine in various
mammalian tissues has revealed that inosine is most abundant in
the brain, where one inosine molecule is present for every 17,000
ribonucleotides of mRNA; the second highest frequency of ino-
sine has been observed in the lung, where one inosine molecule is
present for every 33,000 ribonucleotides of mRNA (Paul and Bass,
1998).
Recently, certain pri-miRNAs have been reported to be sub-
ject to A-to-I editing. Kawahara et al. examined 209 pri-miRNAs
and identiﬁed 47 pri-miRNAs as the targets of A-to-I editing in the
human brain (Kawahara et al., 2008), suggesting that miRNA edit-
ing could have a considerable impact on miRNA-mediated gene
silencing. Most A-to-I editing of pri-miRNAs results in altered
miRNA processing by Drosha and Dicer (Kawahara et al., 2008).
However, in rare cases, such as mir-376, RNA editing causes base
substitution in the seed sequence and generates edited mature
miRNAs with unique target genes and functions different from
those of the unedited miRNAs (Kawahara et al., 2007).
Emerging lines of evidence suggest a link between A-to-I edit-
ing and cancer. Anomalous ADAR activity in cancer may lead to
alterations in the efﬁciency of A-to-I editing. For example, the
glutamate receptor subunit B (GluR-B) is nearly 100% edited at
one position (Q/R site) in the normal brain. In primary glioblas-
toma, this position is substantially under-edited, compared with
normal tissues, because of the decreased activity of ADAR2, which
is responsible for the A-to-I editing of GluR-B (Maas et al., 2001).
Recently, the efﬁciency of A-to-I editing of mir-376a* was found to
be signiﬁcantly attenuated in glioblastoma cells (Choudhury et al.,
2012). Unedited mir-376a* promotes the migration and invasion
of glioma cells,whereas editedmir-376a* suppresses these features.
These results suggest that the attenuation of A-to-I editing of mir-
376a* promotes the invasiveness of glioblastoma. Considering the
relatively high prevalence of inosine in lung mRNA and the fre-
quent A-to-I editing of miRNAs in the brain, it would be tempting
to conduct a large-scale survey to evaluate theA-to-I editing of pri-
miRNAs in normal lung and to analyze the alteration of miRNA
editing and ADAR activity in lung cancer.
CONCLUSIONS AND FUTURE PERSPECTIVES
The twomajor challenges in studying the role of miRNA in cancer
are (i) the identiﬁcation of target genes, and (ii) the elucidation of
the mechanisms that regulate miRNA expression in both normal
and cancer cells. Limited knowledge is available regarding miRNA
transcription, primarily because of inadequate information on the
precise locations of the promoters and transcriptional start sites
of the miRNAs. Approximately half of all miRNAs are intragenic
sequences that are located within the exons, introns, or 3′UTRs of
protein-coding genes. These intragenic miRNAs share promoters
with their host genes and are co-regulated with their host genes, as
in the case of mir-126. The remaining 50% of miRNAs are inter-
genic miRNAs with their own promoters, which have not been
experimentally validated in most cases. Comprehensive analyzes
of the miRNA transcription unit will help to elucidate the tran-
scription factors or epigenetic changes responsible for alterations
in miRNA expression in cancer.
The impairment of the miRNA biogenesis pathway and the
attenuation of A-to-I editing add to the growing complexity of
miRNA deregulation in cancer. Moreover, 3′UTRs of certain
mRNAs are progressively shortened in cancer cells as a result
of changes in alternative cleavage and polyadenylation (APA), a
phenomenon that alters the 3′UTR length. Progressive 3′UTR
shortening in cancer cells may lead to the disruption of miRNA-
mediated gene silencing (Mayr and Bartel, 2009). Understanding
these complexities as well as those of miRNA transcriptional
regulation may lead to the identiﬁcation of novel biomark-
ers and should help to unravel the impact of miRNA in lung
carcinogenesis.
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